$2.11
+0.17
(+8.76%)▲
Insights on Coherus Biosciences Inc
Revenue is up for the last 3 quarters, 32.43M → 74.56M (in $), with an average increase of 33.0% per quarter
Netprofit is up for the last 3 quarters, -74.78M → -39.64M (in $), with an average increase of 41.3% per quarter
In the last 1 year, Seagen, Inc. has given 76.9% return, outperforming this stock by 146.8%
In the last 3 years, Novo Nordisk A/s has given 26.8% return, outperforming this stock by 116.4%
12.56%
Downside
Day's Volatility :14.1%
Upside
1.76%
32.23%
Downside
52 Weeks Volatility :86.99%
Upside
80.8%
Period | Coherus Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -61.58% | -2.6% | 0.0% |
6 Months | -53.25% | 2.2% | 0.0% |
1 Year | -69.88% | -4.3% | -3.4% |
3 Years | -89.49% | 19.1% | -4.7% |
Market Capitalization | 225.0M |
Book Value | - $1.22 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.55 |
PEG Ratio | 0.0 |
Wall Street Target Price | 11.0 |
Profit Margin | -102.86% |
Operating Margin TTM | -4.57% |
Return On Assets TTM | -17.0% |
Return On Equity TTM | -1657.06% |
Revenue TTM | 211.1M |
Revenue Per Share TTM | 2.46 |
Quarterly Revenue Growth YOY | 64.2% |
Gross Profit TTM | -58.4M |
EBITDA | -150.5M |
Diluted Eps TTM | -2.55 |
Quarterly Earnings Growth YOY | -0.75 |
EPS Estimate Current Year | -2.16 |
EPS Estimate Next Year | -0.11 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.11 |
What analysts predicted
Upside of 421.33%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 1.6M | ↓ 99.18% |
Net Income | -238.2M | ↑ 87.04% |
Net Profit Margin | -15.3K% | ↓ 15239.58% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.6M | ↑ 0.0% |
Net Income | -209.3M | ↓ 12.11% |
Net Profit Margin | -13.5K% | ↑ 1852.9% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 356.1M | ↑ 22783.74% |
Net Income | 89.8M | ↓ 142.91% |
Net Profit Margin | 25.23% | ↑ 13478.89% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 475.8M | ↑ 33.63% |
Net Income | 132.2M | ↑ 47.21% |
Net Profit Margin | 27.79% | ↑ 2.56% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 326.6M | ↓ 31.37% |
Net Income | -306.3M | ↓ 331.63% |
Net Profit Margin | -93.81% | ↓ 121.6% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 211.0M | ↓ 35.37% |
Net Income | -326.6M | ↑ 6.63% |
Net Profit Margin | -154.77% | ↓ 60.96% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 60.2M | ↑ 0.06% |
Net Income | -56.3M | ↓ 49.4% |
Net Profit Margin | -93.58% | ↑ 91.47% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 45.4M | ↓ 24.48% |
Net Income | -92.9M | ↑ 64.96% |
Net Profit Margin | -204.41% | ↓ 110.83% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 45.4M | ↓ 0.16% |
Net Income | -66.2M | ↓ 28.65% |
Net Profit Margin | -146.07% | ↑ 58.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 32.4M | ↓ 28.48% |
Net Income | -74.8M | ↑ 12.88% |
Net Profit Margin | -230.55% | ↓ 84.48% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 58.7M | ↑ 81.02% |
Net Income | -42.9M | ↓ 42.67% |
Net Profit Margin | -73.01% | ↑ 157.54% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 74.6M | ↑ 27.0% |
Net Income | -39.6M | ↓ 7.53% |
Net Profit Margin | -53.16% | ↑ 19.85% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 162.6M | ↓ 8.89% |
Total Liabilities | 132.1M | ↓ 17.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 99.5M | ↓ 38.83% |
Total Liabilities | 138.1M | ↑ 4.53% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 408.9M | ↑ 311.12% |
Total Liabilities | 303.7M | ↑ 119.99% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 841.6M | ↑ 105.82% |
Total Liabilities | 560.7M | ↑ 84.61% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 679.3M | ↓ 19.29% |
Total Liabilities | 581.6M | ↑ 3.73% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 480.8M | ↓ 29.22% |
Total Liabilities | 618.3M | ↑ 6.3% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 546.0M | ↓ 7.99% |
Total Liabilities | 568.6M | ↓ 2.1% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 550.9M | ↑ 0.9% |
Total Liabilities | 648.0M | ↑ 13.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 480.8M | ↓ 12.72% |
Total Liabilities | 618.3M | ↓ 4.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 402.4M | ↓ 16.31% |
Total Liabilities | 598.9M | ↓ 3.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 469.6M | ↑ 16.69% |
Total Liabilities | 644.4M | ↑ 7.58% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 583.8M | ↑ 24.32% |
Total Liabilities | 717.4M | ↑ 11.33% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -200.3M | ↓ 20.69% |
Investing Cash Flow | -4.4M | ↓ 32.2% |
Financing Cash Flow | 206.8M | ↓ 8.57% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -159.3M | ↓ 20.48% |
Investing Cash Flow | -1.2M | ↓ 73.1% |
Financing Cash Flow | 105.4M | ↓ 49.02% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 28.4M | ↓ 117.8% |
Investing Cash Flow | -12.7M | ↑ 971.72% |
Financing Cash Flow | 89.4M | ↓ 15.23% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 154.1M | ↑ 443.63% |
Investing Cash Flow | -14.4M | ↑ 13.11% |
Financing Cash Flow | 223.9M | ↑ 150.58% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.4M | ↓ 124.28% |
Investing Cash Flow | -138.4M | ↑ 861.11% |
Financing Cash Flow | 51.9M | ↓ 76.83% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -241.1M | ↑ 544.17% |
Investing Cash Flow | -166.9M | ↑ 20.55% |
Financing Cash Flow | 54.3M | ↑ 4.72% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -50.0M | ↓ 7.42% |
Investing Cash Flow | -880.0K | ↓ 97.53% |
Financing Cash Flow | 721.0K | ↓ 138.87% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -37.1M | ↓ 25.88% |
Investing Cash Flow | -457.0K | ↓ 48.07% |
Financing Cash Flow | 48.9M | ↑ 6677.67% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -100.0M | ↑ 169.49% |
Investing Cash Flow | -129.9M | ↑ 28324.07% |
Financing Cash Flow | 6.6M | ↓ 86.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -68.7M | ↓ 31.24% |
Investing Cash Flow | 17.5M | ↓ 113.49% |
Financing Cash Flow | 3.8M | ↓ 42.3% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -38.9M | ↓ 43.38% |
Investing Cash Flow | 41.4M | ↑ 136.02% |
Financing Cash Flow | 54.3M | ↑ 1328.1% |
Sell
Neutral
Buy
Coherus Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Coherus Biosciences Inc | -35.55% | -53.25% | -69.88% | -89.49% | -82.36% |
![]() Moderna, Inc. | 4.93% | -38.23% | -55.68% | -49.12% | 317.85% |
![]() Regeneron Pharmaceuticals, Inc. | 2.62% | 9.54% | 7.63% | 54.66% | 119.47% |
![]() Novo Nordisk A/s | 7.75% | 29.99% | 71.36% | 209.46% | 351.9% |
![]() Seagen, Inc. | 0.13% | 10.52% | 76.89% | 25.9% | 249.5% |
![]() Vertex Pharmaceuticals Incorporated | -2.03% | 7.65% | 11.07% | 53.76% | 96.32% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Coherus Biosciences Inc | NA | NA | 0.0 | -2.16 | -16.57 | -0.17 | 0.0 | -1.22 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.11 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.51 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.76 | 41.76 | 2.03 | 2.65 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.68 | 26.68 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Coherus Biosciences Inc | Buy | $225.0M | -82.36% | NA | -102.86% |
![]() Moderna, Inc. | Buy | $29.8B | 317.85% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 119.47% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $458.4B | 351.9% | 41.76 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 249.5% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.4B | 96.32% | 26.68 | 35.94% |
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Temasek Holdings Ltd.
Citadel Advisors Llc
JPMorgan Chase & Co
Coherus Biosciences Inc’s price-to-earnings ratio stands at None
Read Morecoherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Organization | Coherus Biosciences Inc |
Employees | 299 |
CEO | Mr. Dennis M. Lanfear |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$2.11
+8.76%
Advisorshares Alpha Dna Equity Sentiment Etf
$2.11
+8.76%
Liberty Tripadvisor Hdg-b
$2.11
+8.76%
Tempo Automation Holdings Inc
$2.11
+8.76%
Falcon's Beyond Global Inc
$2.11
+8.76%
Jaguar Global Growth Corporation I
$2.11
+8.76%
Missfresh Ltd
$2.11
+8.76%
Shuaa Partners Acquisition Corp I
$2.11
+8.76%
Rose Hill Acquisition Corp
$2.11
+8.76%